Ginkgo extract complex with soy phospholipids demonstrates superior bioavailability and improved antioxidant action relative to a standard extract, Indena researchers report at a symposium during the American Society of Pharmacognosy annual meeting in Seattle July 23. The Italian firm maintains the complex is well-tolerated in rats and does not interfere with primary haemostasis at pharmacologically active doses. The compound is a good candidate for future, long-term clinical trials at reduced doses, Indena suggests. The company specializes in the extraction of plant-based active substances for the pharmaceutical, cosmetic and dietary supplement industries
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Eisai and Lilly explain why they disagree with today’s conclusion by the health technology assessment institute, NICE, that the benefits of their respective drugs for Alzheimer’s disease are too small to justify the additional cost to the National Health Service.
Highlights from Day Three of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for the FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
There is a place for using external reference pricing to set prices of advanced therapies, but any such mechanism must take into account the specificities of the Brazilian market and health system.
